QLS-1103
- Generic Name
- QLS-1103
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT05884801
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath